文献速递消化道肿瘤放疗放疗物理与技术

现代时代胰腺癌患者立体定向放疗与常规放疗的比较

Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era.
PubMed 文献 · Adv Radiat Oncol · 2021-07-29

该回顾性研究纳入104例交界可切除/潜在可切除或局部晚期胰腺癌患者,比较新辅助SBRT(中位36.0 Gy/5次)与3D/IMRT(中位50.4 Gy/28次)的临床结局。中位随访22个月,SBRT组中位OS 29.6个月 vs 3D/IMRT组24.1个月,多因素Cox回归显示放疗技术选择与OS无关(aHR=0.5,95%CI 0.2%-1.3%,P=0.18),PFS亦相似(aHR=0.9,95%CI 0.5%-1.8%,P=0.81)。作者结论认为SBRT与常规放疗技术临床结局相似,但仍需前瞻性数据进一步评估SBRT的作用。

要点

  • 104例胰腺癌患者中57例(54.8%)接受SBRT,47例(45.2%)接受3D/IMRT。
  • SBRT组中位OS 29.6个月 vs 3D/IMRT组24.1个月,多因素分析放疗技术与OS无关(aHR=0.5,95%CI 0.2%-1.3%,P=0.18)。
  • 接受手术切除的患者OS更好(aHR=0.3,95%CI 0.1%-0.8%,P=0.01)。

核心结论

  • SBRT与常规放疗技术相比临床结局相似,且治疗时间更短,可减轻患者长期治疗负担。
  • 仍需前瞻性数据以更好地评估SBRT在胰腺癌患者中的作用。

研究设计与样本

  • 回顾性收集德克萨斯大学MD安德森癌症中心的数据。
  • 纳入接受新辅助SBRT(中位36.0 Gy/5次)、3D适形放疗(中位50.4 Gy/28次)或IMRT(中位50.4 Gy/28次)的交界可切除/潜在可切除或局部晚期胰腺癌患者。
  • 共纳入104例患者,SBRT组57例(54.8%),3D/IMRT组47例(45.2%)。
  • 采用Cox回归分析总生存(OS)和无进展生存(PFS)。

主要发现

  • SBRT组患者年龄稍大(中位年龄70.3岁 vs 3D/IMRT组62.7岁)。
  • 两组局部晚期胰腺癌比例相似(SBRT组30例,52.6%;3D/IMRT组24例,51.1%)。
  • 所有患者均接受化疗。
  • SBRT组接受手术切除的比例高于3D/IMRT组(38.6% vs 23.4%)。
  • 中位随访22个月,共60例(57.7%)死亡:SBRT组25例(25/57,43.9%),3D/IMRT组35例(35/47,74.5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性收集数据。
  • 原文结论指出仍需前瞻性数据以更好地评估SBRT在胰腺癌患者中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with pancreatic cancer often receive radiation therapy before undergoing surgical resection. We compared the clinical outcomes differences between stereotactic body radiation therapy (SBRT) and 3-dimensional (3D)/intensity-modulated radiation therapy (IMRT). METHODS AND MATERIALS: We retrospectively collected data from the University of Texas MD Anderson Cancer Center. Patients with borderline resectable/potentially resectable or locally advanced pancreatic cancer receiving neoadjuvant SBRT (median, 36.0 Gy/5fx), 3D conformal radiation (median, 50.4 Gy/28 fx) or IMRT (median, 50.4 Gy/28 fx) were included. Overall survival (OS) and progression-free survival were analyzed using Cox regression. RESULTS: In total, 104 patients were included in our study. Fifty-seven patients (54.8%) were treated with SBRT, and 47 patients (45.2%) were treated with 3D/IMRT. Patients in the SBRT group were slightly older (median age: 70.3 vs 62.7 in the 3D/IMRT group). Both groups had similar proportions of patients with locally advanced pancreatic cancer (SBRT: 30, 52.6%; 3D/IMRT: 24, 51.1%). All patients were treated with chemotherapy. Patients in the SBRT group underwent more surgical resection compared with the 3D/IMRT group (38.6% vs 23.4%, respectively). At a median follow-up of 22 months, a total of 60 patients (57.7%) died: 25 (25/57, 43.9%) in the SBRT group, and 35 (35/47, 74.5%) in the 3D/IMRT group. Median OS was slightly higher in the SBRT group (29.6 months vs 24.1 months in the 3D/IMRT group). On multivariable Cox regression, the choice of radiation therapy technique was not associated with differences in OS (adjusted hazard ratios [aHR] = 0.5; 95% confidence interval [CI], 0.2%-1.3%, P = .18). Moreover, patients that underwent surgical resection had better OS (aHR = 0.3, 95% CI, 0.1%-0.8%, P = .01). Furthermore, progression-free survival was also similar between patients treated with SBRT and those treated with 3D/IMRT (aHR = 0.9, 95% CI, 0.5%-1.8%, P = .81). CONCLUSIONS: SBRT was associated with similar clinical outcomes compared with conventional radiation techniques, despite being delivered over a shorter period of time which would spare patients prolonged treatment burden. Future prospective data are still needed to better assess the role of SBRT in patients with pancreatic cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Abi Jaoude J, Thunshelle CP, Kouzy R, et al. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Adv Radiat Oncol. 2021. PMID: 34934858. doi:10.1016/j.adro.2021.100763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。